Clinical trial
A Study of a New Combination and Schedule of Chemotherapy Drugs for the…
NCT00148122 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00148122 |
|---|---|
| Title | A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer |
| Official title | A Phase II Trial Evaluating Weekly Docetaxel and Capecitabine in Patients With Metastatic or Advanced, Locally, Recurrent Head and Neck Cancer |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Capecitabine |
| Enrollment | 40 |
| Start date | Nov 1, 2002 |
| Primary completion | Aug 1, 2008 |
| Completion | Jul 1, 2010 |
| First posted | Sep 7, 2005 |
| Last update posted | Apr 17, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: